...
首页> 外文期刊>Journal of Clinical Microbiology >Human Immunodeficiency Virus Type 1 Group M Protease in Cameroon: Genetic Diversity and Protease Inhibitor Mutational Features
【24h】

Human Immunodeficiency Virus Type 1 Group M Protease in Cameroon: Genetic Diversity and Protease Inhibitor Mutational Features

机译:喀麦隆人类免疫缺陷病毒1型M组蛋白酶:遗传多样性和蛋白酶抑制剂突变特征

获取原文
   

获取外文期刊封面封底 >>

       

摘要

To establish a baseline for monitoring resistance to protease inhibitors (PIs) and examining the efficacy of their use among persons in Cameroon infected with human immunodeficiency virus type 1 (HIV-1), we analyzed genetic variability and PI resistance-associated substitutions in PCR-amplified protease (PR) sequences in strains isolated from 110 HIV-1-infected, drug-na?ve Cameroonians. Of the 110 strains, 85 were classified into six HIV-1 PR subtypes, A (n = 1), B (n = 1), F (n = 4), G (n = 7), H (n = 1), and J (n = 7), and a circulating recombinant form, CRF02-AG (n = 64). PR genes from the remaining 25 (23%) specimens were unclassifiable, whereas 2% (7 of 301) unclassifiable PR sequences were reported for a global collection. Two major PI resistance-associated mutations, 20M and 24I, were detected in strains from only two specimens, whereas secondary mutations were found in strains from all samples except one strain of subtype B and two strains of CRF02-AG. The secondary mutations showed the typical PI resistance-associated pattern for non-subtype B viruses in both classifiable and unclassifiable PR genes, with 36I being the predominant (99%) mutation, followed by 63P (18%), 20R (15%), 77I (13%), and 10I or 10V (11%). Of these mutations, dual and triple PI resistance-associated substitutions were found in 38% of all the Cameroonian strains. Compared with classifiable PR sequences, unclassifiable sequences had significantly more dual and triple substitutions (64% versus 30%; P = 0.004). Phenotypic and clinical evaluations are needed to estimate whether PI resistance during antiretroviral drug treatment occurs more rapidly in individuals infected with HIV-1 strains harboring multiple PI resistance-associated substitutions. This information may be important for determination of appropriate drug therapies for HIV-1-infected persons in Cameroon, where more than one-third of HIV-1 strains were found to carry dual and triple minor PI resistance-associated mutations.
机译:为了建立基线以监测对蛋白酶抑制剂(PIs)的耐药性并检查在感染了人类免疫缺陷病毒1型(HIV-1)的喀麦隆人中使用蛋白酶抑制剂的功效,我们在PCR-分离自110个HIV-1感染的初次接受药物治疗的喀麦隆人的菌株中的扩增蛋白酶(PR)序列。在这110个菌株中,有85个被分为6种HIV-1 PR亚型,A( n = 1),B( n = 1),F( n = 4),G( n = 7),H( n = 1)和J( n = 7) ,以及循环重组形式CRF02-AG( n = 64)。来自其余25个样本(23%)的PR基因无法分类,而据报道有2%(301个中的7个)无法分类的PR序列已被全球收集。仅从两个标本中检测到两个主要的与PI抗性相关的突变,即20M和24I,而在所有样品中,除了一个B型亚型菌株和两个CRF02-AG菌株,均发现了第二个突变。次要突变显示可分类和不可分类PR基因中非亚型B病毒的典型PI抗性相关模式,其中36I是主要突变(99%),其次是63P(18%),20R(15%), 77I(13%)和10I或10V(11%)。在这些突变中,在所有喀麦隆菌株中有38%发现了与PI抗性相关的双重和三重替代。与可分类的PR序列相比,不可分类的序列具有更多的双取代和三取代(64%比30%; P = 0.004)。需要进行表型和临床评估,以估计抗逆转录病毒药物治疗期间PI耐药性在感染了带有多个PI耐药相关替代的HIV-1菌株的个体中是否更快发生。该信息对于确定喀麦隆针对HIV-1感染者的适当药物疗法可能很重要,在喀麦隆,发现三分之一以上的HIV-1毒株带有双重和三重次要PI抗药性相关突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号